#United States #Menlo Park #Healthcare Leaders #MyOme #Genomic Insights

MyOme Expands Leadership with New Board Appointments

MyOme, a prominent name in genomics innovation and risk modeling, announced the recent appointment of two notable leaders to its Board of Directors—Sam Roosz and Dr. Ravi Thadhani. This strategic addition is anticipated to bolster the company's capabilities as it moves forward in enhancing its artificial intelligence-driven whole-genome health platform.

Strengthening Expertise in Healthcare Technology

Sam Roosz, who co-founded Crescendo Health, is recognized for his dedication to developing patient-centered platforms that facilitate secure contributions of complete health histories to medical research. His prior experience as a co-founder at Datavant, where he established the country’s largest health data ecosystem, reflects his prowess in creating significant enterprise partnerships and navigating high-growth business phases. Roosz shared his enthusiasm for MyOme, stating, “MyOme is unlocking the clinical value of the whole genome and multianalyte analysis in a way that is actionable for patients and providers. I’m excited to support the company’s next phase of growth.”

In tandem, Dr. Ravi Thadhani joins as the Executive Vice President of Clinical Affairs and Chief Medical Officer at Cedars-Sinai. With a career reflecting over 30 years of excellence in academic medicine, clinical operations, and regulatory strategy, he brings with him a wealth of experience and knowledge. Dr. Thadhani has held senior roles at prestigious institutions like Emory University and Harvard Medical School. His deep involvement with data safety monitoring and FDA approval processes aligns closely with the commercial strategy of MyOme, emphasizing the importance of evidence in advancing healthcare technologies.

Vision for Transformative Healthcare

Dr. Thadhani expressed his views on the potential impacts of whole-genome insights, stating, “Whole-genome–powered insights represent one of the most meaningful opportunities to transform how disease is understood, diagnosed, and managed.” Through the integration of monogenic and polygenic insights supported by credible clinical evidence, MyOme is positioned to significantly influence the healthcare landscape.

Matt Rabinowitz, Co-Founder and Executive Chairman of MyOme, highlighted the critical relevance of the new board members, noting that Sam Roosz’s experience with influential health-data platforms and Dr. Thadhani’s leadership within clinical organizations will serve as invaluable assets as the company seeks to incorporate whole-genome and multiomic intelligence into modern medical practice.

Pioneering Genomic Innovation

MyOme utilizes advanced AI technologies paired with integrated risk modeling to transform genomic insights into actionable data, which spans diverse fields including cardiometabolic health, oncology, and pharmacogenomics. This approach aims to enhance clinical care and advance research applications, ultimately contributing to a more efficient healthcare system.

Concluding Thoughts

As MyOme prepares for an ambitious expansion phase, the insights and expertise brought by Sam Roosz and Dr. Ravi Thadhani are set to play a critical role in driving forward personalized medicine initiatives. Their collective experience is likely to catalyze further advancements in genomic healthcare, thereby reshaping how diseases are prevented and managed in the future.

MyOme’s base in Menlo Park, California, underscores its commitment to leading the charge in clinical genome analysis and making a negative impact on healthcare costs through early disease detection and enabled preventive care.

The evolution of MyOme’s Board signifies a commitment to a holistic and knowledgeable approach toward integrating genomic data into everyday health solutions, positioning itself as a vanguard in the healthcare innovation landscape.